Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Fibronectin (FN) plays important roles in the EMT in a variety of cancer cell types. However, the mechanism by which FN expression is regulated in tamoxifen-resistant (TamR) breast cancer cells has not yet been fully elucidated. Aberrant FN expression was associated with poor prognosis in patients with luminal type A breast cancer. In addition, FN was upregulated in TamR cells. To investigate the mechanism by which FN expression is regulated, we assessed the levels of phosphorylated Akt, JNK, and STAT3 and found that they were all increased in TamR cells. Induction of FN expression was dampened by LY294002 or AKT IV in TamR cells. Furthermore, FN expression was increased by constitutively active (CA)-Akt overexpression in tamoxifen-sensitive MCF7 (TamS) cells and colony formation of TamR cells was blocked by AKT IV treatment. Taken together, these results demonstrate that FN expression is upregulated through the PI-3K/Akt pathway in tamoxifen-resistant breast cancer cells.
Abstract
Fibronectin (FN) plays important roles in the EMT in a variety of cancer cell types. However, the mechanism by which FN expression is regulated in tamoxifen-resistant (TamR) breast cancer cells has not yet been fully elucidated. Aberrant FN expression was associated with poor prognosis in patients with luminal type A breast cancer. In addition, FN was upregulated in TamR cells. To investigate the mechanism by which FN expression is regulated, we assessed the levels of phosphorylated Akt, JNK, and STAT3 and found that they were all increased in TamR cells. Induction of FN expression was dampened by LY294002 or AKT IV in TamR cells. Furthermore, FN expression was increased by constitutively active (CA)-Akt overexpression in tamoxifen-sensitive MCF7 (TamS) cells and colony formation of TamR cells was blocked by AKT IV treatment. Taken together, these results demonstrate that FN expression is upregulated through the PI-3K/Akt pathway in tamoxifen-resistant breast cancer cells.
참고문헌 (32)
- Beiki O, "Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: a population-based cohort study", Breast Cancer Res, 14, pp.R5~ (2012)
- Lim E, "The natural history of hormone receptor-positive breast cancer", Oncology (Williston Park), 26, pp.688~694 (2012)
- Regan MM, "Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up", Lancet Oncol, 12, pp.1101~1108 (2011)
- Colditz GA, "Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer", J Natl Cancer Inst, 90, pp.814~823 (1998)
- Paridaens R, "Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer", Cancer, 46, pp.2889~2895 (1980)
- Ravdin PM, "Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen", Cancer Res, 48, pp.1026~1029 (1988)
- Anzick SL, "AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer", Science, 277, pp.965~968 (1997)
- Ruoslahti E, "Fibronectin and its receptors", Annu Rev Biochem, 57, pp.375~413 (1988)
- Jeon M, "Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells", Exp Cell Res, 333, pp.116~126 (2015)
- Kim S, "Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells", Oncol Rep, 32, pp.2230~2236 (2014)
- Dean DC, "Regulation of fibronectin biosynthesis by dexamethasone, transforming growth factor beta, and cAMP in human cell lines", J Cell Biol, 106, pp.2159~2170 (1988)
- Blatti SP, "Induction of fibronectin gene transcription and mRNA is a primary response to growth-factor stimulation of AKR-2B cells", Proc Natl Acad Sci U S A, 85, pp.1119~1123 (1988)
- McDonald JA, "Extracellular matrix assembly", Annu Rev Cell Biol, 4, pp.183~207 (1988)
- Dean DC, "Expression of the fibronectin gene", Am J Respir Cell Mol Biol, 1, pp.5~10 (1989)
- Bae YK, "Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer", Hum Pathol, 44, pp.2028~2037 (2013)
- Kim S, "Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells", Oncol Rep, 34, pp.1613~1619 (2015)
- Ali S, "Endocrine-responsive breast cancer and strategies for combating resistance", Nat Rev Cancer, 2, pp.101~112 (2002)
- Arpino G, "HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study", Clin Cancer Res, 10, pp.5670~5676 (2004)
- Ioachim E, "Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression", Eur J Cancer, 38, pp.2362~2370 (2002)
- Raimondi C, "Epithelialmesenchymal transition and stemness features in circulating tumor cells from breast cancer patients", Breast Cancer Res Treat, 130, pp.449~455 (2011)
- Zheng LH, "Endocrine resistance in breast cancer", Climacteric, 17, pp.522~528 (2014)
- 오선화, "Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells", BMB Reports, 50(3), pp.132~137 (2017), 생화학분자생물학회
- Lee BH, "Transcriptional regulation of fibronectin gene by phorbol myristate acetate in hepatoma cells: a negative role for NF-kappaB", J Cell Biochem, 76, pp.437~451 (2000)
- Chen S, "High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1", Am J Physiol Cell Physiol, 284, pp.C263~C272 (2003)
- Jaiswal BS, "Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation", Cancer Cell, 16, pp.463~474 (2009)
- Campbell IG, "Mutation of the PIK3CA gene in ovarian and breast cancer", Cancer Res, 64, pp.7678~7681 (2004)
- 박서현, "Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells", BMB Reports, 49(1), pp.63~68 (2016), 생화학분자생물학회
- Perez-Tenorio G, "PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer", Clin Cancer Res, 13, pp.3577~3584 (2007)
- Fedele CG, "Inositol polyphosphate 4-phosphatase II regulates PI3K", Akt signaling and is lost in human basal-like breast cancers, 2010, pp.107, 22231~22236
- Miller TW, "Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer", J Clin Oncol, 29, pp.4452~4461 (2011)
- Gyorffy B, "An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients", Breast Cancer Res Treat, 123, pp.725~731 (2010)
- Choi HK, "Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells", Endocr Relat Cancer, 14, pp.293~303 (2007)